Clinical characteristics
| All patients (n=721) | GNRI | P value | |||
| <91.5 (n=240) | 91.5–98.1 (n=242) | >98.1 (n=239) | |||
| Male gender (%) | 71.7 | 68.3 | 67.8 | 79.1 | 0.087 |
| Age (years) | 66±10 | 69±9 | 66±9 | 64±10 | <0.0001 |
| Duration of HD (years) | 3.8 (1.2–10.4) | 6.1 (1.2–11.6) | 3.9 (1.6–9.4) | 2.8 (0.5–6.5) | 0.036 |
| Diabetes (%) | 57.7 | 56.7 | 58.3 | 58.2 | 0.93 |
| Hypertension (%) | 59.8 | 66.3 | 59.1 | 54.0 | 0.023 |
| Dyslipidaemia (%) | 28.7 | 25.4 | 28.9 | 32.6 | 0.25 |
| Smoking (%) | 29.6 | 28.0 | 28.9 | 31.8 | 0.73 |
| Body mass index (kg/m2) | 21.4±3.3 | 18.7±2.2 | 21.5±2.2 | 24.2±2.8 | <0.0001 |
| PAD (%) | 38.7 | 38.3 | 39.7 | 38.1 | 0.93 |
| Stroke (%) | 19.0 | 21.9 | 17.9 | 17.2 | 0.37 |
| GNRI | 94.5±8.7 | 85.1±5.3 | 94.7±1.9 | 103.8±4.8 | <0.0001 |
| Haemoglobin (g/dL) | 10.6±1.3 | 10.4±1.4 | 10.6±1.3 | 10.7±1.2 | 0.12 |
| Albumin (g/dL) | 3.6±0.4 | 3.3±0.3 | 3.6±0.2 | 3.9±0.3 | <0.0001 |
| Total cholesterol (mg/dL) | 168±35 | 169±38 | 167±34 | 167±35 | 0.83 |
| LDL-cholesterol (mg/dL) | 99±28 | 98±29 | 96±25 | 96±30 | 0.81 |
| HDL-cholesterol (mg/dL) | 44±13 | 45±12 | 44±13 | 42±13 | 0.077 |
| CRP (mg/l) | 3.0 (1.0–10.9) | 5.8 (1.1–18.3) | 3.0 (1.0–9.0) | 2.1 (1.0–8.0) | 0.0001 |
| LVEF | 0.59±0.14 | 0.56±0.16 | 0.61±0.13 | 0.60±0.13 | 0.0020 |
| Procedure (%) | 0.069 | ||||
| CABG | 17.9 | 21.3 | 19.0 | 13.4 | |
| PCI | 82.1 | 78.7 | 81.0 | 86.6 | |
| Multivessel disease (%) | 57.6 | 60.8 | 55.8 | 56.1 | 0.45 |
| LMT disease (%) | 6.1 | 6.7 | 5.4 | 6.3 | 0.83 |
| LAD disease (%) | 74.1 | 73.5 | 75.4 | 73.2 | 0.84 |
| Statins (%) | 14.0 | 12.9 | 11.9 | 17.8 | 0.19 |
| β-blocker (%) | 26.3 | 23.3 | 24.3 | 31.8 | 0.12 |
| ARB/ACEI (%) | 43.7 | 42.9 | 44.0 | 44.3 | 0.95 |
| Calcium antagonist (%) | 41.3 | 41.9 | 41.7 | 40.0 | 0.91 |
| Serum CRP | P value | |||
| ≤1.4 mg/L (n=241) | 1.5–7.0 mg/L (n=241) | ≥7.1 mg/L (n=239) | ||
| Male gender (%) | 68.9 | 72.8 | 71.7 | 0.48 |
| Age (years) | 65±9 | 66±10 | 68±10 | 0.010 |
| Duration of HD (years) | 4.4 (0.8–11.8) | 3.6 (1.3–11.6) | 3.5 (1.3–10.2) | 0.98 |
| Diabetes (%) | 58.9 | 52.7 | 61.5 | 0.13 |
| Hypertension (%) | 58.1 | 60.6 | 60.7 | 0.81 |
| Dyslipidaemia (%) | 25.3 | 29.5 | 33.1 | 0.20 |
| Smoking (%) | 29.5 | 30.7 | 27.8 | 0.85 |
| Body mass index (kg/m2) | 21.4±2.9 | 21.6±3.3 | 21.5±3.5 | 0.77 |
| PAD (%) | 34.4 | 37.8 | 43.9 | 0.096 |
| Stroke (%) | 17.2 | 20.5 | 19.3 | 0.64 |
| GNRI | 95.9±7.6 | 95.0±8.3 | 92.6±9.8 | <0.0001 |
| Haemoglobin (g/dL) | 10.8±1.2 | 10.6±1.3 | 10.4±1.4 | 0.14 |
| Albumin (g/dL) | 3.7±0.3 | 3.6±0.3 | 3.5±0.2 | <0.0001 |
| Total cholesterol (mg/dL) | 166±35 | 167±30 | 171±43 | 0.53 |
| LDL-cholesterol (mg/dL) | 93±26 | 96±28 | 104±33 | 0.013 |
| HDL-cholesterol (mg/dL) | 47±14 | 43±12 | 42±11 | 0.0026 |
| CRP (mg/l) | 1.0 (0.8–1.1) | 3.0 (2.0–5.0) | 19.0 (11.0–43.0) | <0.0001 |
| LVEF | 0.62±0.12 | 0.58±0.14 | 0.58±0.15 | 0.018 |
| Procedure (%) | 0.15 | |||
| CABG | 16.7 | 15.3 | 21.8 | |
| PCI | 83.3 | 84.7 | 78.2 | |
| Multivessel disease (%) | 53.9 | 57.3 | 61.5 | 0.24 |
| LMT disease (%) | 5.4 | 7.5 | 5.4 | 0.56 |
| LAD disease (%) | 77.4 | 68.3 | 76.5 | 0.074 |
| Statins (%) | 12.1 | 12.9 | 16.9 | 0.32 |
| β-blocker (%) | 31.5 | 23.0 | 24.2 | 0.11 |
| ARB/ACEI (%) | 45.1 | 42.1 | 43.9 | 0.82 |
| 2calcium antagonist (%) | 44.2 | 38.8 | 40.9 | 0.53 |
Bold data are expressed as mean±SD or median (IQR).
ACEI, Angiotensin-converting-enzyme inhibitor; ARB, Angiotensin II Receptor Blocker; CABG, coronary artery bypass grafting; CRP, C reactive protein; GNRI, geriatric nutritional risk index; HD, haemodialysis; HDL, high density lipoprotein; LAD, left anterior descending artery; LDL, low deinsity lipoprotein; LMT, left main trunk; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention.